23andMe vs Independent DNA Analysis: What You Get

What 23andMe's report actually covers

A 23andMe Health + Ancestry purchase returns a few categories of reports. The exact mix changes over time, but as of 2026 the published categories include:

• Ancestry composition and DNA-relative matching (the genealogy product)
• Wellness reports — a curated subset like caffeine consumption, lactose intolerance, deep sleep, and similar lifestyle traits
• Health predisposition reports for a defined panel of conditions (with FDA authorization for specific variants — Type 2 Diabetes, Late-Onset Alzheimer's, BRCA1/BRCA2 selected variants, others)
• Carrier status reports for a panel of recessive conditions
• Traits reports — physical and behavioral traits with genetic associations

Each of these is well-presented, peer-reviewed, and explicitly bounded by FDA authorizations and 23andMe's curation choices. That curation is the point: 23andMe deliberately limits what they report on so they can stand behind every claim.

What the underlying file contains

Underneath the polished reports, the raw genotype file has hundreds of thousands of variant calls — roughly 600,000 positions across the genome. The reports cover a few hundred to a few thousand of those positions, depending on how you count.

The other ~99% are sitting in the file, waiting. Most don't matter for any given person. Some matter a lot. The hard problem is figuring out which is which without a geneticist.

What independent analysis tools add

Three categories of finding sit outside what 23andMe's curated reports surface.

1. Pharmacogenomics (PGx)

23andMe reports on a small number of FDA-authorized PGx variants (a CYP2C19 panel for clopidogrel, for example). The clinically established PGx universe is much wider — PharmGKB maintains drug-gene interaction tables across SSRIs, opioids, blood thinners, statins, immunosuppressants, anti-epileptics, and more.

Pharmacogenomic interpretation is a clinical-grade workflow ordered through a prescriber. Genosight does not provide pharmacogenomic guidance — for any question about how a medication will affect you, work directly with your prescribing clinician or pharmacist.

2. Lifestyle SNPs across more categories

23andMe's wellness panel is selective. Independent tools that maintain a curated SNP catalog can surface variants relevant to:

• Methylation (MTHFR, MTR, MTRR, COMT, CBS)
• Detoxification (CYP1A1, CYP1A2, GSTM1, GSTT1, NAT2)
• Sodium sensitivity (ADD1, AGTR1, ACE)
• Inflammation (TNF, IL6, CRP variants)
• Vitamin D metabolism (VDR, CYP2R1, GC)
• Iron handling (HFE, TMPRSS6)
• Exercise response (ACTN3, ACE)

These aren't disease predictions — they're lifestyle-modifiable signals that can inform supplement choice, diet pattern, and monitoring frequency. 23andMe touches a few of them; an independent tool with a curated catalog covers more.

3. ClinVar disease variants outside the FDA-authorized panel

ClinVar catalogs variants of clinical significance — far more than the panel 23andMe is authorized to report on. Independent tools that scan ClinVar against your raw file can surface variants in genes 23andMe doesn't include, with the appropriate caveats around confidence (gold-star ratings) and the limits of consumer-array detection.

The crucial framing here: independent ClinVar lookup is informational, not diagnostic. Consumer arrays don't reliably detect every clinically relevant variant — many disease-associated mutations are rare or are insertions/deletions that the array doesn't call well. A clean independent ClinVar scan is reassuring; a flag is a starting point for clinical-grade testing, not a diagnosis.

When it's worth the second look

Independent analysis is worth your time if any of the following apply:

• You're starting or switching a medication where PGx evidence exists (most psychiatry, blood thinners, several pain medications, statins).
• You have a chronic condition that your 23andMe report doesn't speak to and you want context.
• You're family-planning and a healthcare provider or genetic counsellor has recommended clinical-grade carrier screening as the next step.
• You're optimizing lifestyle (supplements, diet, training) and want gene-aware guidance instead of generic recommendations.
• You're prepping for a clinical visit and want a structured PDF you can hand to a clinician.

If you only wanted ancestry, or your 23andMe wellness panel covered everything you cared about, independent analysis adds little.

What independent tools can't do

Important to be honest about the ceiling. Independent analysis of a consumer-array file:

• Can't replace clinical-grade sequencing for conditions that need it
• Can't reliably catch rare disease variants — the array doesn't include them
• Can't substitute for a genetic counselor for inheritance planning or actionable findings
• Can't interpret structural variants, copy-number variants, or repeat expansions

Treat independent analysis as a much wider lens on the same dataset, not as an upgrade to a different dataset. For that, whole-genome sequencing is the right next step. (What consumer arrays can and can't catch.)

How GenoSight handles the second look

GenoSight is purpose-built for this use case: take the raw file you already have and surface the variants 23andMe doesn't report on, with synthesis grounded in your full health profile.

The pipeline runs three engines (curated lifestyle SNPs, PharmGKB, ClinVar) against your file, then folds in your personal-profile context (family history, symptoms, supplements, allergies, habits, goals) so the report is about you specifically, not a generic genome. The full pipeline is described in how the AI synthesis actually runs, and a findings-grounded chat lets you ask follow-up questions per finding.

Key takeaways

• 23andMe's reports cover a curated subset of your raw file — the underlying genotype file has hundreds of thousands of additional variant calls.
• Independent analysis tools add three categories: pharmacogenomics (PharmGKB), wider lifestyle SNP coverage, and ClinVar disease-variant scanning beyond the FDA-authorized panel.
• Worth the second look if you're starting a medication with PGx evidence, optimizing lifestyle, family-planning, or prepping for a clinical visit.
• Independent analysis is informational, not diagnostic — for clinical decisions, clinical-grade testing and a genetic counselor remain the standard.
• GenoSight runs the three engines against your existing file and synthesizes findings against a nine-domain health profile — same variant, different recommendation depending on context.